Insmed (NASDAQ:INSM) Reaches New 12-Month High – Should You Buy?

Insmed Incorporated (NASDAQ:INSM)’s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $100.00 and last traded at $99.52, with a volume of 444591 shares changing hands. The stock had previously closed at $98.73.

Wall Street Analyst Weigh In

INSM has been the subject of several research analyst reports. Jefferies Financial Group reissued a “buy” rating on shares of Insmed in a report on Tuesday, June 10th. Guggenheim restated a “buy” rating and set a $101.00 price objective on shares of Insmed in a research note on Tuesday, February 25th. Leerink Partners boosted their target price on shares of Insmed from $100.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, June 10th. The Goldman Sachs Group lifted their target price on Insmed from $100.00 to $112.00 and gave the company a “buy” rating in a research note on Wednesday, June 11th. Finally, Wells Fargo & Company upped their target price on Insmed from $107.00 to $119.00 and gave the company an “overweight” rating in a report on Wednesday, June 11th. One equities research analyst has rated the stock with a sell rating and eighteen have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $104.81.

Insmed Stock Up 2.1%

The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company has a market cap of $18.36 billion, a price-to-earnings ratio of -18.03 and a beta of 0.80. The business has a fifty day moving average price of $71.41 and a two-hundred day moving average price of $73.59.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $92.82 million for the quarter, compared to analyst estimates of $91.63 million. During the same period last year, the business earned ($1.06) EPS. The company’s quarterly revenue was up 22.9% on a year-over-year basis. On average, equities analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insider Buying and Selling

In other Insmed news, insider Michael Alexander Smith sold 409 shares of the business’s stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $65.61, for a total value of $26,834.49. Following the transaction, the insider now directly owns 91,794 shares in the company, valued at $6,022,604.34. The trade was a 0.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Martina M.D. Flammer sold 9,925 shares of the firm’s stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $65.47, for a total transaction of $649,789.75. Following the sale, the insider now directly owns 86,596 shares of the company’s stock, valued at approximately $5,669,440.12. The trade was a 10.28% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 301,182 shares of company stock worth $24,289,380 in the last quarter. 3.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Insmed

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. National Bank of Canada FI lifted its position in shares of Insmed by 9.7% in the 4th quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company’s stock worth $115,000 after purchasing an additional 147 shares during the period. M&T Bank Corp lifted its position in shares of Insmed by 4.7% during the 1st quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company’s stock valued at $252,000 after acquiring an additional 147 shares during the period. Snowden Capital Advisors LLC boosted its stake in Insmed by 2.5% during the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company’s stock worth $456,000 after acquiring an additional 158 shares in the last quarter. Steward Partners Investment Advisory LLC grew its holdings in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares during the period. Finally, Cullen Frost Bankers Inc. grew its holdings in Insmed by 164.9% in the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 221 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.